Vera Therapeutics, Inc. (VERA) Current Ratio
- Current ratio · latest quarter: Value 10.92×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.92× | Current assets / current liabilities. $527.49M ÷ $48.32M ≈ 10.92× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 527.49M USD | Assets, Current |
| Current obligations | 48.32M USD | Liabilities, Current |
| Cash and equivalents | 48.88M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 450.29M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 14.57M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $527.49M | $48.32M | $48.88M | $450.29M | (m) | (m) | $14.57M | (m) | 10.92× |
| 2026-03-31 | $615.80M | $45.15M | $114.35M | $482.41M | (m) | (m) | $13.91M | (m) | 13.64× |
| 2025-12-31 | $728.88M | $53.45M | $354.73M | $359.86M | (m) | (m) | $21.90M | (m) | 13.64× |
| 2025-09-30 | $511.31M | $41.88M | $57.77M | $439.62M | (m) | (m) | $17.95M | (m) | 12.21× |
| 2025-06-30 | $571.35M | $33.55M | $49.12M | $507.71M | (m) | (m) | $13.16M | (m) | 17.03× |
| 2025-03-31 | $606.08M | $21.89M | $55.09M | $534.74M | (m) | (m) | $9.26M | (m) | 27.68× |
| 2024-12-31 | $651.22M | $25.37M | $92.65M | $548.21M | (m) | (m) | $7.67M | (m) | 25.67× |
| 2024-09-30 | $364.13M | $26.46M | $27.26M | $326.05M | (m) | (m) | $4.60M | (m) | 13.76× |
| 2024-06-30 | $394.75M | $18.42M | $25.09M | $359.30M | (m) | (m) | $4.66M | (m) | 21.43× |
| 2024-03-31 | $416.37M | $14.54M | $69.11M | $334.56M | (m) | (m) | $5.21M | (m) | 28.63× |
| 2023-12-31 | $172.02M | $22.30M | $45.68M | $115.03M | (m) | (m) | $11.12M | (m) | 7.71× |
| 2023-09-30 | $171.62M | $24.62M | $27.44M | $132.50M | (m) | (m) | $12.30M | (m) | 6.97× |
| 2023-06-30 | $190.61M | $26.84M | $33.89M | $147.13M | (m) | (m) | $13.28M | (m) | 7.10× |
| 2023-03-31 | $204.45M | $23.53M | $137.38M | $59.77M | (m) | (m) | $5.33M | (m) | 8.69× |
| 2022-12-31 | $125.70M | $25.60M | $43.46M | $71.19M | (m) | (m) | $11.99M | (m) | 4.91× |
| 2022-09-30 | $124.98M | $15.92M | $30.48M | $83.94M | (m) | (m) | $7.01M | (m) | 7.85× |
| 2022-06-30 | $142.34M | $17.28M | $50.43M | $81.50M | (m) | (m) | $7.08M | (m) | 8.24× |
| 2022-03-31 | $157.74M | $19.97M | $111.51M | $39.43M | (m) | (m) | $7.33M | (m) | 7.90× |
| 2021-12-31 | $82.54M | $7.69M | $79.67M | $0.00 | (m) | (m) | $1.39M | (m) | 10.73× |
| 2021-09-30 | $89.76M | $4.04M | $86.19M | (m) | (m) | (m) | $964.00K | (m) | 22.21× |
| 2021-06-30 | $95.88M | $3.77M | $91.63M | (m) | (m) | (m) | $1.72M | (m) | 25.42× |
| 2021-03-31 | $51.53M | $3.75M | $49.51M | (m) | (m) | (m) | $1.44M | (m) | 13.73× |
| 2020-12-31 | $54.26M | $2.41M | $53.65M | (m) | (m) | (m) | $909.00K | (m) | 22.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |